JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2018, 67(5):182-191 | DOI: 10.36290/csf.2018.026

Metal complexes in medicine and pharmacy - the past and the present I

Ladislav Habala*, Jindra Valentová
Katedra chemickej teórie liečiv, Farmaceutická fakulta UK, Bratislava, Slovak Republic

Metals and their compounds have been exploited in medicine since the dawn of history. All metals (or their substances) exert some kind of biological activity. Metal complexes exhibit a number of unique properties as compared to purely organic substances, stemming from the presence of the metal atom and the variable arrangement of ligands around this central atom. The goal of this brief survey is to provide basic overview of the area of metallopharmacy, aimed at specialists in pharmacy and chemistry as well as at the general educated public. The first part concentrates on some historical aspects of metallopharmacy and on current application of metals in the therapy of infectious diseases and in diagnostics.

Keywords: bioinorganic chemistry; metallopharmaceuticals; metal complexes; Chemotherapy
Grants and funding:

Práca bola podporovaná Vedeckou grantovou agentúrou MŠVVaŠ SR a SAV, grant VEGA 1/0346/16.

Received: November 21, 2018; Accepted: December 20, 2018; Published: May 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Habala L, Valentová J. Metal complexes in medicine and pharmacy - the past and the present I. Čes. slov. farm. 2018;67(5-6):182-191. doi: 10.36290/csf.2018.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kaim W., Schwederski B., Klein A. Bioinorganic chemistry: inorganic elements in the chemistry of life. Chichester: John Wiley & Sons Ltd 2013.
    2. Crichton R. R. Biological inorganic chemistry. A new introduction to molecular structure and function. Amsterdam: Elsevier 2012.
    3. Bertini I., Gray H. B., Stiefel E. I., Valentine J. S. Biological inorganic chemistry: structure and reactivity. Sausalito: University Science Books 2007.
    4. Taylor D. M., Williams D. R. Trace element medicine and chelation therapy. Cambridge: The Royal Society of Chemistry 1995. Go to original source...
    5. Frieden E. (ed.) Biochemistry of the essential ultratrace elements. New York: Plenum Press 1984. Go to original source...
    6. Jones C., Thornback J. Medicinal applications of coordination chemistry. Cambridge: The Royal Society of Chemistry 2007. Go to original source...
    7. Gielen M., Tiekink E. R. T. Metallotherapeutic drugs and metal-based diagnostic agents - the use of metals in medicine. Chichester: John Wiley & Sons Ltd 2005. Go to original source...
    8. Mjos K. D., Orvig C. Metallodrugs in medicinal inorganic chemistry. Chem. Rev. 2014; 114, 4540-4563. Go to original source... Go to PubMed...
    9. Sneader W. Drug discovery. A history. Chichester: John Wiley & Sons 2005. Go to original source...
    10. Beutler E. History of iron in medicine. Blood Cells Mol. Dis. 2002; 29, 297-308. Go to original source... Go to PubMed...
    11. Higby G. J. Gold in medicine. A review of its use in the West before 1900. Gold Bull. 1982; 15, 130-140. Go to original source... Go to PubMed...
    12. Benedek T. G. The history of gold therapy for tuberculosis. J. Hist. Med. Allied Sci. 2004; 59, 50-89. Go to original source...
    13. Lemire J. A., Harrison J. J., Turner R. J. Antimicrobial activity of metals: mechanisms, molecular targets and applications. Nat. Rev. Microbiol. 2013; 11, 371-384. Go to original source... Go to PubMed...
    14. Riegel-Futyra A., Dąbrowski J. M., Mazuryk O., Śpiewak K., Kyzioł A., Pucelik B., Brindell M., Stochel G. Bioinorganic antimicrobial strategies in the resistance era. Coord. Chem. Rev. 2017; 351, 76-117. Go to original source...
    15. Farrar W. V., Williams A. R. A history of mercury. In: McAuliffe C. A. (ed.) The chemistry of mercury. London: The Macmillan Press 1977. Go to original source...
    16. Lykknes A., Kvittingen L. Arsenic: not so evil after all? J. Chem. Ed. 2003; 80, 497-500. Go to original source...
    17. Riethmiller S. From atoxyl to salvarsan: searching for the magic bullet. Chemotherapy 2005; 51, 234-242. Go to original source... Go to PubMed...
    18. Williams K. J. The introduction of 'chemotherapy' using arsphenamine - the first magic bullet. J. Royal Soc. Med. 2009; 102, 343-348. Go to original source... Go to PubMed...
    19. Levinson A. S. The structure of salvarsan and the arsenic-arsenic double bond. J. Chem. Ed. 1977; 54, 98-99. Go to original source...
    20. Lloyd N. C., Morgan H. W., Nicholson B. K., Ronimus R. S. The composition of Ehrlich's salvarsan: resolution of a century-old debate. Angew. Chem. Int. Ed. 2005; 44, 941-944. Go to original source... Go to PubMed...
    21. Rao Y., Li R. H., Zhang D. Q. A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Sci. China Life Sci. 2013; 56, 495-502. Go to original source... Go to PubMed...
    22. Alexander J. W. History of the medical use of silver. Surg. Infect. 2009; 10, 289-292. Go to original source... Go to PubMed...
    23. Nowack B., Krug H. F., Height M. 120 years of nanosilver history: implications for policy makers. Environ. Sci. Technol. 2011; 45, 1177-1183. Go to original source... Go to PubMed...
    24. Vosmanská V., Kolářová K., Švorčík V. Porovnání antibakteriální aktivity krytů ran dotovaných stříbrem. Chem. Listy 2017; 111, 804-808.
    25. Stathopoulou M. K., Banti C. N., Kourkoumelis N., Hatzidimitriou A. G., Kalampounias A. G., Hadjikakou S. K. Silver complex of salicylic acid and its hydrogel-cream in wound healing chemotherapy. J. Inorg. Biochem. 2018; 181, 41-55. Go to original source... Go to PubMed...
    26. Klasen H. J. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns 2000; 26, 131-138. Go to original source... Go to PubMed...
    27. Chernousova S., Epple M. Silver as antibacterial agent: ion, nanoparticle, and metal. Angew. Chem. Int. Ed. 2013; 52, 1636-1653. Go to original source... Go to PubMed...
    28. Möhler J. S., Sim W., Blaskovich M. A. T., Cooper M. A., Ziora Z. M. Silver bullets: a new lustre on an old antimicrobial agent. Biotechnol. Adv. 2018; 36, 1391-1411. Go to original source... Go to PubMed...
    29. Hendre A. D., Taylor G. W., Chávez E. M., Hyde S. A systematic review of silver diamine fluoride: effectiveness and application in older adults. Gerodontology 2017; 34, 411-419. Go to original source... Go to PubMed...
    30. Hordyjewska A., Popiołek Ł., Kocot J. The many 'faces' of copper in medicine and treatment. Biometals 2014; 27, 611-621. Go to original source... Go to PubMed...
    31. Vincent M., Hartemann P., Engels-Deutsch M. Antimicrobial applications of copper. Int. J. Hyg. Environ. Health 2016; 219, 585-591. Go to original source... Go to PubMed...
    32. O'Gorman J., Humphreys H. Application of copper to prevent and control infection. Where are we now? J. Hosp. Infect. 2012; 81, 217-223. Go to original source... Go to PubMed...
    33. Borkow G., Gabbay J. Copper as a biocidal tool. Curr. Med. Chem. 2005; 12, 2163-2175. Go to original source... Go to PubMed...
    34. Li H., Sun H. Recent advances in bioinorganic chemistry of bismuth. Curr. Opin. Chem. Biol. 2012; 16, 74-83. Go to original source... Go to PubMed...
    35. Yang N., Sun H. Biocoordination chemistry of bismuth: Recent advances. Coord. Chem. Rev. 2007; 251, 2354-2366. Go to original source...
    36. Keogan D. M., Griffith D. M. Current and potential applications of bismuth-based drugs. Molecules 2014; 19, 15258-15297. Go to original source... Go to PubMed...
    37. Habala L., Devínsky F., Egger A. Metal complexes as urease inhibitors. J. Coord. Chem. 2018; 71, 907-940. Go to original source...
    38. Frézard F., Demicheli C., Ribeiro R. R. Pentavalent antimonials: New perspectives for old drugs. Molecules 2009; 14, 2317-2336. Go to original source... Go to PubMed...
    39. Tamás M. J. Cellular and molecular mechanisms of antimony transport, toxicity and resistance. Environ. Chem. 2016; 13, 955-962. Go to original source...
    40. Li F., Collins J. G., Keene F. R. Ruthenium complexes as antimicrobial agents. Chem. Soc. Rev. 2015; 44, 2529-2542. Go to original source... Go to PubMed...
    41. Navarro M., Gabbiani C., Messori L., Gambino D. Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. Drug Discov. Today 2010; 15, 1070-1078. Go to original source... Go to PubMed...
    42. Zhang L., Carroll P., Meggers E. Ruthenium complexes as protein kinase inhibitors. Org. Lett. 2004; 6, 521-523. Go to original source... Go to PubMed...
    43. Mishra A. K., Mishra L. (eds.) Ruthenium chemistry. Singapore: Pan Stanford Publishing Pte. Ltd. 2018. Go to original source...
    44. Amolegbe S. A., Akinremi C. A., Adewuyi S., Lawal A., Bamigboye M. O., Obaleye J. A. Some nontoxic metal-based drugs for selected prevalent tropical pathogenic diseases. J. Biol. Inorg. Chem. 2017; 22, 1-18. Go to original source... Go to PubMed...
    45. Kotek J., Lukeš I. Cheláty pro využití v biomedicínských oborech. Chem. Listy 2010; 104, 1163-1174.
    46. Caschera L., Lazzara A., Piergallini L., Ricci D., Tuscano B., Vanzulli A. Contrast agents in diagnostic imaging: present and future. Pharmacol. Res. 2016; 110, 65-75. Go to original source... Go to PubMed...
    47. Vallabhajosula S. Molecular imaging. Radiopharmaceuticals for PET and SPECT. Berlin - Heidelberg: Springer-Verlag 2009.
    48. Saha G. B. Fundamentals of nuclear pharmacy. New York: Springer Science 2010. Go to original source...
    49. Zanzonico P. Principles of nuclear medicine imaging: Planar, SPECT, PET, multi-modality, and autoradiography systems. Radiat. Res. 2012; 177, 349-364. Go to original source... Go to PubMed...
    50. Khalil M. M., Tremoleda J. L., Bayomy T. B., Gsell W. Molecular SPECT imaging: An overview. Int. J. Mol. Imaging 2011; Article ID 796025. Go to original source... Go to PubMed...
    51. Kohlíčková M., Jedináková-Křížová V., Melichar F. Komplexní sloučeniny technecia - jejich využití v přípravě radiofarmak a některé farmakokinetické vlastnosti. Chem. Listy 1998; 92, 643-655.
    52. Schwochau K. Technetium: chemistry and radiopharmaceutical applications. Weinheim: Wiley-VCH Verlag GmbH 2000. Go to original source...
    53. Saha G. B. Basics of PET imaging. Physics, chemistry, and regulations. New York: Springer Science 2010. Go to original source...
    54. Vāvere A. L., Lewis J. S. Cu-ATSM: A radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007; 43, 4893-4902. Go to original source... Go to PubMed...
    55. Westbrook C. MRI at a glance. Chichester: John Wiley & Sons Ltd 2016.
    56. Laurent S., Henoumont C., Stanicki D., Boutry S., Lipani E., Belaid S., Muller R. N., Elst L. V. MRI contrast agents. From molecules to particles. Singapore: Springer Nature 2017. Go to original source...
    57. Kim H.-K., Lee G. H., Chang Y. Gadolinium as an MRI contrast agent. Future Med. Chem. 2018; 10, 639-661. Go to original source... Go to PubMed...
    58. Zhang Z., Shrikumar A. N., McMurry T. J. Gadolinium meets medicinal chemistry: MRI contrast agent development. Curr. Med. Chem. 2005; 12, 751-778. Go to original source... Go to PubMed...
    59. Giovenzana G. B., Lattuada L., Negri R. Recent advances in bifunctional paramagnetic chelates for MRI. Isr. J. Chem. 2017; 57, 825-832. Go to original source...
    60. Bonnet C. S., Tóth É. Smart contrast agents for magnetic resonance imaging. Chimia 2016; 70, 102-108. Go to original source... Go to PubMed...
    61. Lux J., Sherry A. D. Advances in gadolinium-based MRI contrast agent designs for monitoring biological processes in vivo. Curr. Opin. Chem. Biol. 2018; 45, 121-130. Go to original source... Go to PubMed...
    62. Sherry A. D., Wu Y. The importance of water exchange rates in the design of responsive agents for MRI. Curr. Opin. Chem. Biol. 2013; 17, 167-174. Go to original source... Go to PubMed...
    63. Pullicino R., Das K. Is it safe to use gadolinium-based contrast agents in MRI? J. R. Coll. Physicians Edinb. 2017; 47, 243-246. Go to original source... Go to PubMed...
    64. Kelkar S. S., Reineke T. M. Theranostics: combining imaging and therapy. Bioconjugate Chem. 2011; 22, 1879-1903. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.